Artesian Projects
In October 2005, Cardiome announced completion of the acquisition of Artesian Therapeutics, Inc., further to the letter of intent (“LOI”) announced on August 29, 2005.
Artesian was founded in March of 2002 to discover and develop bi-functional small-molecule drugs for the treatment of cardiovascular disease. Artesian’s lead program is focused on a series of dualpharmacophore compounds designed to simultaneously inhibit the cardiac phosphodiesterase enzyme (PDE3), causing inotropic effects, while inhibiting the L-Type Calcium channel to protect against calcium overload.